CTNM.US Contineum Therapeutics, Inc. Class A Common Stock

Healthcare Pharmaceuticals USA Stocks
10.95 USD
Close of Nov 14, 2026
6.73 17.79
Market cap
USD 387M
P/E
-
P/B
1.57x
ROE
-26.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CTNM.US undervalued?

Graham number

The Graham number of Contineum Therapeutics, Inc. Class A Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Contineum Therapeutics, Inc. Class A Common Stock fundamental analysis

No fundamental analysis for Contineum Therapeutics, Inc. Class A Common Stock yet.

Contineum Therapeutics, Inc. Class A Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibi…

Full company profile